This article is part of the supplement: Basic science, rationale, background and future of abatacept
The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
-
* Corresponding author: Eric M Ruderman e-ruderman@northwestern.edu
Arthritis Research & Therapy 2005, 7(Suppl 2):S21-S25 doi:10.1186/ar1688
Accesses
- Last 30 days: 90 accesses
- Last year: 883 accesses
- All time: 11815 accesses
Cited by
BioMed Central: 4 citations
|
Review
Recent developments in the immunobiology of rheumatoid arthritis Anna K Andersson, Ching Li, Fionula M Brennan Arthritis Research & Therapy 2008, 10:204 (14 March 2008) |
|
Research article
Arthritis suppression by NADPH activation operates through an interferon-β pathway Peter Olofsson, Annika Nerstedt, Malin Hultqvist, Elisabeth C Nilsson, Sofia Andersson, Anna Bergelin, Rikard Holmdahl BMC Biology 2007, 5:19 (9 May 2007) In arthritis-susceptible rats, a natural alcohol, phytol, protects against arthritis by boosting NADPH oxidase via an interferon-beta associated pathway, in contrast to the interferon-gamma regulation of the immune system that drives arthritis progression.
|
|
Review
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis? Vivianne Malmström, Christina Trollmo, Lars Klareskog Arthritis Research & Therapy 2005, 7(Suppl 2):S15-S20 (16 March 2005) |
|
Introduction
The science of rheumatoid arthritis: a prelude Josef S Smolen Arthritis Research & Therapy 2005, 7(Suppl 2):S1-S3 (16 March 2005) |